Augmenter of liver regeneration reduces mitochondria-derived ROS and NLRP3 inflammasome activation through PINK1/Parkin-mediated mitophagy in ischemia-reperfusion-induced renal tubular injury

Author:

Zhu Dongju,Zhong Jie,Gong Xuefeng,Wu Xiang

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Biochemistry (medical),Cell Biology,Clinical Biochemistry,Pharmaceutical Science,Pharmacology

Reference44 articles.

1. Mehta RL, Burdmann EA, Cerdá J, Feehally J, Finkelstein F, García-García G, Godin M, Jha V, Lameire NH, Levin NW, Lewington A, Lombardi R, Macedo E, Rocco M, Aronoff-Spencer E, Tonelli M, Zhang J, Remuzzi G (2016) Recognition and management of acute kidney injury in the International Society of Nephrology 0by25 Global Snapshot: a multinational cross-sectional study. Lancet 387(10032):2017–2025. https://doi.org/10.1016/S0140-6736(16)30240-9

2. Malek M, Nematbakhsh M (2015) Renal ischemia/reperfusion injury; from pathophysiology to treatment. J Renal Inj Prev 4(2):20–27. https://doi.org/10.12861/jrip.2015.06

3. Sutterwala FS, Ogura Y, Szczepanik M, Lara-Tejero M, Lichtenberger GS, Grant E, Bertin J, Coyle AJ, Galán JE, Askenase PW, Flavell R (2006) Critical role for NALP3/CIAS1/cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 24(3):317–327. https://doi.org/10.1016/j.immuni.2006.02.004

4. Kim HJ, Lee DW, Ravichandran K, Keys DO, Akcay A, Nguyen Q, He ZB, Jani A, Ljubanovic D, Edelstein CL (2013) NLRP3 inflammasome knockout mice are protected against ischemic but not cisplatin-induced acute kidney injury. J Pharmacol Exp Ther 346(3):465–472. https://doi.org/10.1124/jpet.113.205732

5. Tang CY, Han HL, Yan MJ, Zhu SY, Liu J, Liu ZW, He LY, Tan JQ, Liu Y, Liu H, Sun L, Duan SB, Peng YM, Liu FY, Yin XM, Zhang ZH, Dong Z (2018) PINK1-PRKN/PARK2 pathway of mitophagy is activated to protect against renal ischemia-reperfusion injury. Autophagy 14(5):880–897. https://doi.org/10.1080/15548627.2017.1405880

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3